X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the amendment Cipla and Pulmatrix agreed to stop patient enrollment of the Ph2b study of PUR1900 (itraconazole) at 8 subjects and close the study. Cipla will take sole responsibility for development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis.
Lead Product(s): Itraconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PUR1900
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: Undisclosed Upfront Cash: $22.0 million
Deal Type: Agreement January 08, 2024
Details:
PUR3100 is an orally inhaled formulation of dihydroergotamine (DHE) engineered with iSPERSE™ technology, which is investigated for the treatment of acute migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: PUR3100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
PUR3100 dry powder inhaler is under development as an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™ for the acute treatment of migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: PUR3100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
PUR3100 (dihydroergotamine) is under development as an orally inhaled DHE engineered with iSPERSE™ for the acute treatment of migraine. The PUR3100 formulation is designed to disperse to the deep lung and rapidly enter the systemic circulation.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: PUR3100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
PUR1800 is a narrow spectrum Kinase Inhibitor, engineered with our iSPERSE™ technology, being developed for the treatment of acute exacerbations in chronic obstructive pulmonary disease (AECOPD). PUR1800 targets p38 MAP kinases (p38MAPK), Src kinases, and Syk kinases.
Lead Product(s): PUR1800
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PUR1800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
PUR3100 (Dihydroergotamine) is under development as an orally inhaled DHE engineered with iSPERSE™ for the acute treatment of migraine. The PUR3100 formulation is designed to disperse to the deep lung and rapidly enter the systemic circulation.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: PUR3100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: PUR3100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
PUR1800, a narrow-spectrum kinase inhibitor was well-tolerated and there were no observed safety signals. The preliminary PK data indicate that PUR1800 results in low and consistent systemic exposure when administered via oral inhalation.
Lead Product(s): PUR1800
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PUR1800
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicines Evaluation Unit
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Pulmatrix's product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer.
Lead Product(s): Itraconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Pulmazole
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2021
Details:
Under the terms of the Agreement, the Company has granted Sensory Cloud an exclusive, worldwide, royalty bearing license to PUR 003 and PUR 006 (NasoCalm).
Lead Product(s): PUR 003,PUR 006
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sensory Cloud
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
